{"log_id": 621663675129719492, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.001241, "average": 0.983882, "min": 0.829466}, "location": {"width": 850, "top": 219, "height": 35, "left": 247}, "words": "和25mg/kg组雌雄大鼠肝细胞瘤(包括腺瘤和癌)的发生率明显增加。人长期服用氯雷他定"}, {"probability": {"variance": 1.4e-05, "average": 0.997549, "min": 0.986443}, "location": {"width": 326, "top": 272, "height": 27, "left": 243}, "words": "时,上述发现的临床意义尚不明确"}, {"probability": {"variance": 5e-06, "average": 0.998503, "min": 0.992879}, "location": {"width": 145, "top": 320, "height": 29, "left": 248}, "words": "【药代动力学】"}, {"probability": {"variance": 0.01906, "average": 0.949533, "min": 0.475056}, "location": {"width": 278, "top": 363, "height": 29, "left": 238}, "words": "1.健康成年人的药代动力学"}, {"probability": {"variance": 0.000118, "average": 0.994658, "min": 0.951121}, "location": {"width": 832, "top": 404, "height": 36, "left": 259}, "words": "据文献报道:本品口服迅速吸收。健康成年人每天1次10mg,连续服药10天,本品与其"}, {"probability": {"variance": 0.000401, "average": 0.99327, "min": 0.882971}, "location": {"width": 853, "top": 453, "height": 35, "left": 237}, "words": "主要代谢物脱羧乙氧氯雷他定的达峰时间(Tmax)分别为1.3和2.5h。单次用药,食物分"}, {"probability": {"variance": 0.002295, "average": 0.982744, "min": 0.749509}, "location": {"width": 854, "top": 505, "height": 31, "left": 235}, "words": "别使氯雷他定和脱羧乙氧氯雷他定的AC增加40%和15%,Tmax延迟1h,峰浓度不受食物"}, {"probability": {"variance": 2e-06, "average": 0.999013, "min": 0.99714}, "location": {"width": 68, "top": 554, "height": 25, "left": 234}, "words": "的影响"}, {"probability": {"variance": 2.6e-05, "average": 0.998083, "min": 0.968079}, "location": {"width": 799, "top": 599, "height": 35, "left": 287}, "words": "用药10天内,大约80%的药物以其代谢物的形式等比例分布于尿液和粪便中,几乎"}, {"probability": {"variance": 0.00038, "average": 0.994626, "min": 0.87554}, "location": {"width": 855, "top": 650, "height": 33, "left": 231}, "words": "所有患者,其代谢物的AUC高于原型药物的AUC,对于健康成年人(n=54),氯雷他定及脱"}, {"probability": {"variance": 0.000575, "average": 0.99133, "min": 0.83718}, "location": {"width": 854, "top": 699, "height": 33, "left": 231}, "words": "羧乙氧氯雷他定的平均清除半衰期(t2)分别为8.4h(3-20h)和28h(8.8-92h),一般第5天"}, {"probability": {"variance": 7.7e-05, "average": 0.997288, "min": 0.947411}, "location": {"width": 759, "top": 748, "height": 34, "left": 229}, "words": "血药浓度达稳定,由于本品具有首过效应,因此药代动力学参数的个体差异较大"}, {"probability": {"variance": 0.008619, "average": 0.963477, "min": 0.556349}, "location": {"width": 797, "top": 796, "height": 38, "left": 288}, "words": "人肝脏微粒体酶的离体试验表明,本品主要通过细胞色素P4503ACWP3A4)代谢为脱"}, {"probability": {"variance": 0.002513, "average": 0.982376, "min": 0.692954}, "location": {"width": 859, "top": 847, "height": 36, "left": 226}, "words": "羧乙氧氯雷他定,少部分由细胞色素P4502D6(CYP2D65代谢,当与CYP3A4抑制剂酮康唑"}, {"probability": {"variance": 0.005524, "average": 0.980386, "min": 0.628205}, "location": {"width": 850, "top": 898, "height": 31, "left": 226}, "words": "同服时,本品主要通过CYP2D6代谢成脱羧氯雷他定,本品与酮康唑、红霉素C两者均为CYP3A4"}, {"probability": {"variance": 0.013977, "average": 0.949887, "min": 0.474267}, "location": {"width": 797, "top": 947, "height": 32, "left": 226}, "words": "抑制剂)或西米替丁(CYP2D6和CYP3A4抑制剂)同时服用,血浆氯雷他定浓度增加"}, {"probability": {"variance": 0.00053, "average": 0.991497, "min": 0.872221}, "location": {"width": 777, "top": 997, "height": 30, "left": 284}, "words": "12位健康老人(6678岁)口服本面浆氯雷他定和脱羧氯雷他定的AUC和Cm"}, {"probability": {"variance": 0.000969, "average": 0.988539, "min": 0.80529}, "location": {"width": 854, "top": 1046, "height": 30, "left": 223}, "words": "均比健康成人高出50%氯雷他定和脱羧氯雷他定的半衰期分别为18.2h(6.737h)和"}, {"probability": {"variance": 0.007544, "average": 0.961086, "min": 0.677731}, "location": {"width": 137, "top": 1097, "height": 24, "left": 223}, "words": "17.5h(11-38h"}, {"probability": {"variance": 0.001516, "average": 0.987808, "min": 0.84754}, "location": {"width": 320, "top": 1143, "height": 27, "left": 280}, "words": "与6名肾功能正常(肌酐清除率"}, {"probability": {"variance": 0.000149, "average": 0.992936, "min": 0.95323}, "location": {"width": 404, "top": 1142, "height": 34, "left": 672}, "words": "n)的受试者相比,12位慢性肾功能不全患"}, {"probability": {"variance": 0.002869, "average": 0.977201, "min": 0.746509}, "location": {"width": 853, "top": 1190, "height": 35, "left": 220}, "words": "者(肌酐清除率≤30m/min)口服本品后,氯雷他定的AUC和Cmax增加约73%,脱羧乙氧"}, {"probability": {"variance": 0.000645, "average": 0.990211, "min": 0.8272}, "location": {"width": 853, "top": 1239, "height": 36, "left": 219}, "words": "氯雷他定的AUC和Cmax增加约120%,血浆氯雷他定和脱羧乙氧氯雷他定的tmax分别为7.6h"}, {"probability": {"variance": 2.7e-05, "average": 0.997625, "min": 0.972236}, "location": {"width": 711, "top": 1289, "height": 33, "left": 219}, "words": "和23.9h,血透并不影响本品在慢性肾功能不全患者体内的药代动力学过程"}, {"probability": {"variance": 3e-06, "average": 0.998519, "min": 0.990122}, "location": {"width": 769, "top": 1337, "height": 35, "left": 274}, "words": "与健康受试者相比,7名慢性酒精性肝病患者服用本品,血浆氯雷他定的AUC和C"}, {"probability": {"variance": 0.003726, "average": 0.988426, "min": 0.607665}, "location": {"width": 856, "top": 1386, "height": 35, "left": 216}, "words": "增加1倍,而脱羧乙氧氯雷他定无明显改变,氯雷他定和脱羧乙氧氯雷他定的血浆t1分别"}, {"probability": {"variance": 0.000231, "average": 0.992012, "min": 0.938486}, "location": {"width": 499, "top": 1437, "height": 28, "left": 215}, "words": "为24h和3h,而且t随着肝损伤程度的加重而延长"}, {"probability": {"variance": 8.1e-05, "average": 0.996113, "min": 0.957769}, "location": {"width": 857, "top": 1476, "height": 34, "left": 213}, "words": "2.12岁以下儿童口服氯雷他定糖浆的药代学文献报道,6-12岁儿童口服氯雷他定糖浆的药"}, {"probability": {"variance": 0.000208, "average": 0.99605, "min": 0.92426}, "location": {"width": 509, "top": 1510, "height": 26, "left": 215}, "words": "代学与成年人类似,13名儿童志愿者(8-12岁)口服"}, {"probability": {"variance": 0.000361, "average": 0.989417, "min": 0.939995}, "location": {"width": 292, "top": 1512, "height": 31, "left": 778}, "words": "10ml氯雷他定糖浆的药代动力"}, {"probability": {"variance": 2e-05, "average": 0.997052, "min": 0.978702}, "location": {"width": 675, "top": 1541, "height": 30, "left": 213}, "words": "学参数(AUC和Cmax)与成年人口服等量糖浆的药代学参数无显著差异"}, {"probability": {"variance": 0.000183, "average": 0.99517, "min": 0.928305}, "location": {"width": 794, "top": 1573, "height": 33, "left": 254}, "words": "文献报道,2-5岁儿童(n=18)口服本品的药代动力学参数与成年人类似,单次给予5"}, {"probability": {"variance": 0.000129, "average": 0.996031, "min": 0.929658}, "location": {"width": 761, "top": 1607, "height": 30, "left": 212}, "words": "氯雷他定糖浆与成年人或8岁以上儿童口服10mg片剂或糖浆的AUC和Cmax类似"}, {"probability": {"variance": 3.1e-05, "average": 0.997745, "min": 0.967718}, "location": {"width": 814, "top": 1638, "height": 37, "left": 255}, "words": "国外研究表明1~2岁儿童应用2.5mg本品后的药代动力学特征与年龄较大的儿童及成"}], "language": 3}